|
1
|
Wolff AC, Hammond ME, Schwartz JN, Hagerty
KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer
A, et al: American Society of Clinical Oncology/College of American
Pathologists guideline recommendations for human epidermal growth
factor receptor 2 testing in breast cancer. J Clin Oncol.
25:118–145. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kawai A, Woodruff J, Healey JH, Brennan
MF, Antonescu CR and Ladanyi M: SYT-SSX gene fusion as a
determinant of morphology and prognosis in synovial sarcoma. N Engl
J Med. 338:153–160. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Moatamed NA, Nanjangud G, Pucci R, Lowe A,
Shintaku IP, Shapourifar-Tehrani S, Rao N, Lu DY and Apple SK:
Effect of ischemic time, fixation time, and fixative type on
HER2/neu immunohistochemical and fluorescence in situ hybridization
results in breast cancer. Am J Clin Pathol. 136:754–761. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Japanese Society of Pathology, . Guideline
for HER2 examination of gastric cancer and breast cancer. 1st.
Kanehara Press Co.; Tokyo: 2015
|
|
5
|
Owens MA, Horten BC and Da Silva MM: HER2
amplification ratios by fluorescence in situ hybridization and
correlation with immunohistochemistry in a cohort of 6556 breast
cancer tissues. Clin Breast Cancer. 5:63–69. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Abaza HM, Youssef SR, Saad AA, Kamal GM,
Hegazy MG, Ibrahim RI and Annaka LM: Detection of 14q32
rearrangements in multiple myeloma, using simultaneous FISH
analysis combined with immunofluorescence. Hematol Oncol Stem Cell
Ther. 8:56–63. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Weber-Matthiesen K, Winkemann M,
Müller-Hermelink A, Schlegelberger B and Grote W: Simultaneous
fluorescence immunophenotyping and interphase cytogenetics: A
contribution to the characterization of tumor cells. J Histochem
Cytochem. 40:171–175. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Weber-Matthiesen K, Deerberg J,
Müller-Hermelink A, Schlegelberger B and Grote W: Rapid
immunophenotypic characterization of chromosomally aberrant cells
by the new FICTION method. Cytogenet Cell Genet. 63:123–125. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Nomoto J, Hiramoto N, Kato M, Sanada M,
Maeshima AM, Taniguchi H, Hosoda F, Asakura Y, Munakata W,
Sekiguchi N, et al: Deletion of the TNFAIP3/A20 gene detected by
FICTION analysis in classical Hodgkin lymphoma. BMC Cancer.
12:4572012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mostegl MM, Richter B, Dinhopl N and
Weissenböck H: Influence of prolonged formalin fixation of tissue
samples on the sensitivity of chromogenic in situ hybridization. J
Vet Diagn Invest. 23:1212–1216. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Downs-Kelly E, Pettay J, Hicks D, Skacel
M, Yoder B, Rybicki L, Myles J, Sreenan J, Roche P, Powell R, et
al: Analytical validation and interobserver reproducibility of
EnzMet GenePro: A second-generation bright-field metallography
assay for concomitant detection of HER2 gene status and protein
expression in invasive carcinoma of the breast. Am J Surg Pathol.
29:1505–1511. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ni R, Mulligan AM, Have C and O'Malley FP:
PGDS, a novel technique combining chromogenic in situ hybridization
and immunohistochemistry for the assessment of ErbB2 (HER2/neu)
status in breast cancer. Appl Immunohistochem Mol Morphol.
15:316–324. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Reisenbichler ES, Horton D, Rasco M, Andea
A and Hameed O: Evaluation of dual immunohistochemistry and
chromogenic in situ hybridization for HER2 on a single section. Am
J Clin Pathol. 137:102–110. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Nitta H, Kelly BD, Padilla M, Wick N,
Brunhoeber P, Bai I, Singh S, Ranger-Moore J, Bieniarz C, Tsuda H
and Grogan TM: A gene-protein assay for human epidermal growth
factor receptor 2 (HER2): Brightfield tricolor visualization of
HER2 protein, the HER2 gene, and chromosome 17 centromere (CEN17)
in formalin-fixed, paraffin-embedded breast cancer tissue sections.
Diagn Pathol. 7:602012. View Article : Google Scholar : PubMed/NCBI
|
